Medical Cannabis for Children UK: Epilepsy, Eligibility and Access

Medical Cannabis for Children in the UK: A Comprehensive Guide

Introduction

The landscape of medical cannabis prescribing for children in the United Kingdom has undergone significant changes since 2018. What was once considered entirely prohibited is now, in carefully regulated circumstances, a therapeutic option for some of the most severely affected young patients. This guide explores the current position, landmark cases, and what families need to know about accessing cannabis-based medicines for children.

The Landmark Cases: Alfie Dingley and Billy Caldwell

Two remarkable children fundamentally altered UK cannabis legislation. In 2018, eight-year-old Alfie Dingley and twelve-year-old Billy Caldwell became the faces of a campaign that would change everything. Both boys suffered from severe, treatment-resistant epilepsy, experiencing dozens of seizures daily despite trying multiple conventional medications.

When their families travelled abroad for cannabis oil treatment and saw dramatic improvements, they campaigned publicly for change. The media attention, combined with medical evidence, forced the government’s hand. Within weeks of the cases becoming national news, the Home Office reclassified cannabis as a Schedule 2 drug, permitting doctors to prescribe cannabis-based medicines for medical purposes.

Whilst neither boy’s case resulted in NHS prescriptions initially, their courage and their parents’ advocacy opened a door that had been firmly closed. Today, both boys’ stories remain central to discussions about paediatric cannabis medicine in the UK. They demonstrated that sometimes, when all conventional options have failed, cannabis deserves serious consideration.

Which Conditions Qualify in Children?

In the UK, medical cannabis for children is extraordinarily restricted. The primary condition is severe, treatment-resistant epilepsy. This is epilepsy that has failed to respond to at least two appropriately chosen conventional antiepileptic drugs at adequate doses.

The vast majority of children prescribed cannabis-based medicines have one of two specific epilepsy syndromes: Dravet syndrome or Lennox-Gastaut syndrome. Both are devastating, rare genetic conditions that typically emerge in infancy or early childhood, characterised by frequent, difficult-to-control seizures.

Beyond epilepsy, the evidence base for other conditions in children remains extremely limited. Some private specialists may consider cannabis for other treatment-resistant conditions, but the NHS position is notably restrictive. For more information about the legal framework, see our guide to cannabis law in the UK.

Accessing Cannabis for Your Child: The General Process

The pathway to accessing medical cannabis for a child in the UK is complex and depends on whether you pursue NHS or private routes. Most families find that obtaining specialist assessment is the crucial first step. This typically means being under the care of a paediatric neurologist with expertise in intractable epilepsy.

Before any cannabis-based medicine is considered, your child must have genuinely exhausted conventional options. Documentation of previous treatments, dosages, and outcomes is essential. You’ll need comprehensive medical records, including EEGs, neuroimaging, and a detailed seizure diary.

The process requires patience, advocacy, and often significant emotional resilience from families. Many parents report feeling unsupported by their local services and having to pursue private consultation.

NHS Prescribing for Children: The Reality

NHS prescribing of cannabis-based medicines to children remains exceptionally rare. Whilst specialists can legally prescribe, few do. As of recent years, fewer than ten children in the entire UK have received NHS prescriptions for cannabis-based medicines.

The barriers are substantial. Many consultants lack experience or confidence with cannabis medicines. There are concerns about long-term effects in developing brains. Research specific to children remains limited. Additionally, prescribing requires navigating complex commissioning arrangements with local integrated care boards.

When NHS prescriptions do occur, they’re typically for Epidyolex, a pharmaceutical-grade CBD product. These cases usually involve children with Dravet syndrome or Lennox-Gastaut syndrome whose conditions have proven utterly resistant to everything else. The decision to prescribe represents genuine clinical desperation on the part of specialists—a recognition that without cannabis, the child’s situation is unsustainable.

Private Prescribing for Children

Private prescribing represents the more common route for families seeking cannabis-based medicines for children. Several private clinics in the UK now have paediatric expertise, particularly in London and other major cities. Private consultations typically cost £300–£500 for initial assessment, with follow-up appointments and prescriptions incurring additional costs.

Private best UK cannabis clinics are often more willing to engage with cannabis medicine, particularly those with backgrounds in neurology or cannabis medicine research. However, quality varies significantly. Families must thoroughly vet any private provider, checking credentials, asking about their specific experience with paediatric patients, and understanding their approach.

Private prescriptions must then be dispensed by licensed pharmacies authorised to dispense controlled cannabis products. Costs for the actual medicine vary but can range from £500–£3,000 monthly depending on the product and dosage.

CBD-Only Versus Full Cannabis Products

An important distinction exists between cannabidiol (CBD) alone and full-spectrum cannabis products containing multiple cannabinoids including THC. For children, CBD-only products are generally preferred by specialists and families alike.

CBD is non-intoxicating and carries a significantly better safety profile in young brains. It has the most robust evidence base for childhood epilepsy. Full-spectrum products, containing THC alongside CBD, may be more effective for some adults but are considered riskier in children given concerns about THC’s effects on developing neural systems.

Most children who receive cannabis-based medicines in the UK take CBD-only products, either as Epidyolex or from licensed producers supplying private prescriptions.

Epidyolex: The NHS-Approved Option

Epidyolex is a pharmaceutical-grade CBD oral solution approved by the MHRA and available on the NHS for specific indications. It’s specifically licensed for adjunctive treatment of seizures associated with Dravet syndrome or Lennox-Gastaut syndrome in patients aged one year and older.

Epidyolex represents the most accessible NHS option because it’s already an approved medicine, not requiring specialist commissioners to fund an unlicensed drug. Despite this advantage, NHS prescriptions remain uncommon due to gatekeeping by local services and consultant reluctance.

The medication is dosed carefully based on body weight, with gradual titration to minimise side effects. The most common side effect is sedation, though liver function monitoring is required. For families accessing Epidyolex privately, expect costs of £800–£1,200 monthly.

Parental Experiences and Advocacy

Parents of children with severe epilepsy navigate extraordinary challenges. Many describe feeling abandoned by conventional medicine after exhausting all licensed options. The decision to pursue cannabis is rarely taken lightly—it typically represents a last hope after years of frustration.

Positive experiences are often transformative. Parents report reduced seizure frequency, improved alertness, better sleep, and improved quality of life. These aren’t miraculous cures—most children continue having seizures—but the improvements can be genuinely life-changing.

Parental advocacy groups have become crucial in pushing for policy change and supporting families. These organisations provide peer support, share information, and campaign for better access to medical cannabis in the UK for their children.

The Future of Paediatric Cannabis Prescribing

The future remains uncertain but potentially hopeful. Research into cannabis-based medicines for childhood epilepsy continues, particularly in Europe. As evidence accumulates and more specialists gain experience, attitudes may gradually shift.

However, significant barriers remain. Long-term safety data in children is limited. Many medical professionals remain sceptical. Political and cultural hesitations about cannabis persist, even in medical contexts.

Realistic expectations suggest gradual, incremental progress rather than dramatic transformation. As paediatric cannabis medicine matures as a field, availability may improve, costs may decrease, and